基于直线加速器的立体定向放疗治疗脑转移瘤(包括多发和大病灶)的急性毒性发生率低:一项回顾性分析
该回顾性研究分析了2019年5月至2022年2月在本机构接受直线加速器立体定向放疗的315例脑转移瘤患者共439次治疗、2161个病灶,≥2级和≥3级即时副作用分别占3.6%和1.6%,最大肿瘤体积较大、原发灶非肺癌和乳腺癌、治疗前有神经系统症状者更常见,结论认为该疗法安全但严重并发症罕见但可能,需密切随访。
要点
- ≥2级和≥3级即时副作用分别发生在16例(3.6%)和7例(1.6%)治疗中。
- ≥3级即时副作用包括3级恶心1例、3级新发部分性和全面性癫痫4例、3级梗阻性脑积水1例和5级颅内出血1例。
- 最大肿瘤体积较大、原发灶非肺癌和乳腺癌、治疗前有神经系统症状的患者即时副作用更常见。
核心结论
- 基于直线加速器的立体定向放疗治疗脑转移瘤(包括多发和大病灶)是安全的,即时副作用发生率低。
- 立体定向放疗后立即发生严重并发症罕见但可能,因此治疗开始后需要密切随访。
研究设计与样本
- 本回顾性研究回顾了2019年5月至2022年2月在本机构接受立体定向放疗的315例脑转移瘤患者的医疗记录。
- 共对2161个脑转移瘤进行了439次立体定向放疗。
- 感兴趣的结果是即时副作用,定义为立体定向放疗期间或立体定向放疗结束后14天内出现的新发或加重症状。
主要发现
- ≥2级和≥3级即时副作用分别发生在16例(3.6%)和7例(1.6%)治疗中。
- 在63次针对10个或以上病灶(范围10-40)的治疗中,发生1例(1.6%)即时副作用。
- 在22次针对最大肿瘤体积>10 cc的病灶的治疗中,发生2例(9.1%)即时副作用。
- ≥3级即时副作用包括3级恶心1例、3级新发部分性和全面性癫痫4例、3级梗阻性脑积水1例和5级颅内出血1例。
- 即时副作用在最大肿瘤体积较大、原发部位非肺癌和乳腺癌、治疗前有神经系统症状的患者中更常见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on acute toxicities after stereotactic radiotherapy (SRT) for brain metastases, including multiple and large lesions, are lacking. We aimed to evaluate the incidence and nature of toxicities immediately after SRT using a linear accelerator. METHODS: This retrospective study reviewed the medical records of 315 patients with brain metastases treated with SRT at our institution between May 2019 and February 2022. In total, 439 SRT sessions were performed for 2161 brain metastases. The outcome of interest was immediate side effects (ISEs), defined as new or worsening symptoms occurring during SRT or within 14 days after the end of SRT. RESULTS: Grade ≥ 2 and ≥ 3 ISEs occurred in 16 (3.6%) and 7 (1.6%) cases, respectively. Among 63 treatments for 10 or more lesions (range: 10-40), 1 (1.6%) ISE occurred. Among 22 treatments for lesions with a maximum tumor volume of > 10 cc, 2 (9.1%) ISEs occurred. Grade ≥ 3 ISEs included 1, 4, 1, and 1 cases of grade 3 nausea, grade 3 new-onset partial and generalized seizures, grade 3 obstructive hydrocephalus, and grade 5 intracranial hemorrhage, respectively. ISEs were more common in patients with a larger maximum tumor volume, primary sites other than lung and breast cancer, and pre-treatment neurological symptoms. CONCLUSION: SRT using a linear accelerator for brain metastases, including multiple and large lesions, is safe, with a low incidence of ISEs. Serious complications immediately after SRT are rare but possible; therefore, careful follow-up is necessary after treatment initiation.
引用
- Ikawa T, Kanayama N, Arita H, et al. Linear accelerator-based stereotactic radiotherapy for brain metastases, including multiple and large lesions, carries a low incidence of acute toxicities: a retrospective analysis. Radiat Oncol. 2023. PMID: 37165431. doi:10.1186/s13014-023-02262-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。